A
Alcista
Alcista · 25%PTCT
$146.32
Precio del escenario
$60.990
+1.348 (+2.21%)Al cierre
Loading chart…
- Máximo
- 62.310
- Apertura
- 61.080
- Precio medio ponderado por volumen
- 61.06
- Volumen
- 1.05M
- Capitalización
- 2.66B
- Mínimo
- 59.880
- Importe
- 64.23M
- EV/EBITDA, TTM
- 7.44
PTC Therapeutics, Inc. is a global biopharmaceutical company. It is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its ST-920, or isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease.
Análisis de IA of PTC Therapeutics Inc (PTCT)
ComprarPTC Therapeutics Inc is a good buy right now due to its recent acquisition of ST-920, which has shown promising clinical results and received favorable regulatory designations, potentially enhancing its market position. The current price of $64.7 is significantly below the average analyst price target of $96, indicating a potential upside of 48%. Additionally, the company has a gross margin of 91.19%, suggesting strong profitability potential. However, the main risk is its negative net income margin of 1.03%, indicating ongoing profitability challenges that investors should monitor closely.
Recomendaciones de analistas (8)
+28.18% de potencial alcista
Mantener
2 Comprar
5 Mantener
1 Vender
Actual: 60.99
Mínimo
54.00
Promedio
78.18
Máximo
118.00
RBC Capital
Sector Perform
$75
2026-10-08
RBC Capital
2026-10-08
Precio objetivo
$75
Sector Perform
Leerink
Superar al mercado
$98
2026-09-14
Leerink
2026-09-14
Precio objetivo
$98
Superar al mercado
Wells Fargo
Sobreponderar
$109
2026-08-13
Wells Fargo
2026-08-13
Precio objetivo
$109
Sobreponderar
BofA
Comprar
$96
2026-07-31
BofA
2026-07-31
Precio objetivo
$96
Comprar
Morgan Stanley
Sobreponderar
$104
2026-07-31
Morgan Stanley
2026-07-31
Precio objetivo
$104
Sobreponderar
Métricas de valoración
El PER previsto actual de PTC Therapeutics Inc (PTCT) es 22.73, frente a su media de 5 años de -3.47.
Escenarios de precio de Alphio AI para PTCT
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con PTCT en cartera
Cronología de eventos
Noticias
9.510-15PRnewswirePTC Therapeutics to Host Q3 2026 Financial Results Webcast
4.510-08CNBCSmall Caps Struggle as Nasdaq Holds Strong Amid Treasury Yield Surge
5.009-25PRnewswirePTC Therapeutics Approves Employee Stock Incentive Plan
5.009-25NewsfilterPTC Therapeutics Approves Employee Stock Incentive Plan
8.509-22NASDAQ.COMPTC Therapeutics Completes Acquisition of ST-920 Gene Therapy for Fabry Disease
Preguntas frecuentes sobre PTCT, respondidas por Alphio AI
PTC Therapeutics, Inc. is a global biopharmaceutical company. It is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its ST-920, or isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
PTC Therapeutics Inc is a good buy right now due to its recent acquisition of ST-920, which has shown promising clinical results and received favorable regulatory designations, potentially enhancing its market position. The current price of $64.7 is significantly below the average analyst price target of $96, indicating a potential upside of 48%. Additionally, the company has a gross margin of 91.19%, suggesting strong profitability potential. However, the main risk is its negative net income margin of 1.03%, indicating ongoing profitability challenges that investors should monitor closely.
8 analysts cover PTCT: 2 rate it Buy, 5 Hold and 1 Sell. The average price target is 78.18.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.